-
Nature Immunology: When cancer-fighting T cells are depleted, they may change sides
Time of Update: 2023-02-03
Image: Dr. Greg Delgoffe, associate professor of immunology at Pitt College of Medicine and director of the Center for Oncology Microenvironment at UPMC Hillman Cancer CenterWhen T cells, the immune system's main anticancer agent, work overtime to fight tumors, they enter a state of exhaustion and no longer work properly.
-
Cell Discovery: Revealing the molecular mechanism by which adenosine receptor A2BR binds endogenous and selective ligands
Time of Update: 2023-02-01
Adenosine (ADO) is widely distributed in various tissues and organs of the human body, and regulates a variety of important physiological and pathological processes in the human body by acting on ade
-
Ying Wang's research group from the Institute of Nutrition and Health discovered a new mechanism by which fatty acid metabolism regulates the formation of hair follicle stem cell microenvironment
Time of Update: 2022-12-30
202201949 On December 11, 2022, the international academic journal Advanced Science published a research paper entitled "SCD1 Sustains Homeostasis of Bulge Niche via Maintaining Hemidesmosomes in Basal Keratinocytes" by Wang Ying's research group and Shi Yufang, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences.
-
The use of DNA biomarkers to detect early HPV-positive oropharyngeal cancer has limitations
Time of Update: 2022-11-04
"Association of Pretreatment Circulating Tumor Tissue–Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer Oropharyngeal cancer caused by human papillomavirus (HPV) has risen sharply in recent years, replacing tobacco use and alcohol abuse as the main drivers of new cases.
-
The latest paper by Zhu Di’s team at Fudan University: RORγt agonists enhance anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancer
Time of Update: 2022-05-15
On April 23, 2022, Researcher Zhu Di of Fudan University published a paper titled "RORγt agonist enhances anti-PD-1 therapy by promoting monocyte" in the Journal of Experimental & Clinical Cancer Research (IF=11.
-
Use CRISPR technology to modify tumor cells in situ and reshape macrophages to achieve effective tumor immunotherapy
Time of Update: 2022-01-08
722 ) in the field of nanotechnology published an online publication titled " CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer" " Immunotherapy " (using CRISPR technology to modify tumor cells in situ to reshape macrophages to achieve effective tumor immunotherapy) research results .
-
Professor Li Yonghong: Tumor-reducing treatment of primary tumor of metastatic prostate cancer
Time of Update: 2021-12-08
Summary The treatment of primary tumor cytoreduction for metastatic prostate cancer may prolong survival and reduce local symptoms; published research data must be viewed objectively; patients who may benefit must be identified; the trauma that may be caused by surgery must be weighed; surgery and It is not the only option; it is recommended to adopt the method of clinical research and cautiously carry out radical prostatectomy .
-
Acquired 4 targeted therapies including TIGIT antibody and Gilead to expand its oncology pipeline for US$725 million
Time of Update: 2021-12-02
Today, Gilead Sciences and Arcus Biosciences jointly announced that Gilead has exercised its option to obtain multiple R&D projects in Arcus’ clinical R&D pipeline, including two monoclonal antibodies domvanalimab and AB308 that target TIGIT, and small Molecular therapy etrumadenant and quemliclustat .
-
Nature reviews the pathogenesis, biology and role of iron death in diseases
Time of Update: 2021-11-02
This unique cell death program is driven by iron-dependent phospholipid peroxidation, and is affected by a variety of cellular metabolic pathways (including redox homeostasis, iron metabolism, mitochondrial activity, amino acid, lipid and sugar metabolism) and various diseases-related The regulation of signal pathways .
-
First in class selective SIRPα inhibitor phase I results are positive
Time of Update: 2021-10-11
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn September 16, OSE and Boehringer Ingelheim (BI) jointly announced the first-in-class selective SIRPα inhibitor BI 765063 combined with PD-1 monoclonal antibody BI 754091 (ezabenlimab) to treat patients with advanced solid tumors in phase I dose escalation positive data .
-
BMC Cancer: Is it too difficult to enhance the effect of PD-1 immunotherapy on prostate cancer
Time of Update: 2021-09-29
The effect of eIF5B silencing on prostate cancer cellsThe results showed that compared with RWPE-1, the expression of eIF5B and PD-L1 in PC-3 and VCaP cells was significantly increased , so we chose PC-3 and VCaP for follow-up experiments .
-
Clinical & Translational Gastroenterology: Obesity is not associated with increased risk of serious infections in patients with inflammatory bowel disease after biotherapy
Time of Update: 2021-08-27
This study confirms that after adjusting for comorbidities and disease characteristics, obesity is not independently associated with the increased risk of severe infection in IBD patients treated with biologics .
-
Do these three aspects well to improve the quality of colonoscopy
Time of Update: 2021-06-11
High-quality colonoscopy is the key to colonoscopy The colorectal cancer screening guidelines published on Gastroenterology in 2017 strongly recommend that doctors use adenoma detection rate (ADR) as quality control indicators when performing colonoscopy screening.
-
To Biao Hengrui and Sanofi
Time of Update: 2021-05-22
Medical Network News, May 8 Recently, the official website of the State Food and Drug Administration showed that the docetaxel injection of Sichuan Meida Kangjiale Pharmaceutical was approved as a supplementary application.
-
Merck and Day One collaborate to develop MEK inhibitor Pimasertib
Time of Update: 2021-03-24
Day One plans to further advance the Phase 1/2 study of the drug to evaluate the safety of Pimasertib in combination with DAY101 for the treatment of patients ≥12 years of age with relapsed, progressive or refractory solid tumors and abnormal MAPK pathway , Tolerability and preliminary efficacy.
